The IDH1-R132H mutation is implicated in the development of various tumors. Whether cisplatin, a common chemotherapeutic agent, induces more significant renal toxicity in individuals with the IDH1-R132H mutation remains unclear. In this study, we observed that the IDH1-R132H mutation exacerbates mitochondrial lipid peroxidation and dysfunction in renal tubules, rendering the kidneys more susceptible to cisplatin-induced ferroptosis. The IDH1-R132H mutation increases methylation of the Ndufa1 promoter, thereby suppressing NDUFA1 transcription and translation. This suppression disrupts NDUFA1's interaction with FSP1, reducing its resistance to cisplatin-induced tubular epithelial cell death. As a consequence, ROS accumulates, lipid peroxidation occurs, and ferroptosis is triggered, thereby promoting acute kidney injury. In summary, this study elucidates a novel mechanism underlying cisplatin-induced nephrotoxicity and provides valuable insights for the development of personalized treatment strategies for tumor patients carrying the IDH1-R132H mutation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41418-024-01381-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update.
J Neurooncol
January 2025
Department of Neurosurgery, NYU Langone Health and NYU Grossman School of Medicine, 530 1st Avenue, Skirball Suite 8R, New York, NY, 10016, USA.
Unlabelled: QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma.
Question: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?
Recommendation: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis.
Targeting the mutation in gliomas by CRISPR/Cas precision base editing.
Neurooncol Adv
November 2024
Laboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Centre, University Hospital and University of Zurich, Zurich, Switzerland.
Background: Gliomas, the most frequent malignant primary brain tumors, lack curative treatments. Understanding glioma-specific molecular alterations is crucial to develop novel therapies. Among them, the biological consequences of the isocitrate dehydrogenase 1 gene mutation ( ) remain inconclusive despite its early occurrence and widespread expression.
View Article and Find Full Text PDFIDH1 R132H and TP53 R248Q Mutations Modulate Glioma Cell Migration and Adhesion on Different ECM Components.
Int J Mol Sci
November 2024
School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok 690922, Russia.
Mutations in IDH1 and TP53 have a significant impact on glioma prognosis and progression; however, their roles in tumor cell invasion in terms of interactions with particular components of the extracellular matrix (ECM) are still unclear. Using gene editing protocol based on CRISPR-Cas 9 with cytidine deaminase, we introduced point mutations into U87MG glioblastoma cells to establish modified cell lines with heterozygous IDH1 R132H, homozygous TP53 R248Q and heterozygous IDH1 R132H, homozygous TP53 R248Q genotypes. A comparative study of cell migration on major ECM components was carried out by high-content microscopy.
View Article and Find Full Text PDFHistopathologic and molecular profile of gliomas diagnosed in Lagos, Nigeria.
Neurooncol Pract
December 2024
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MinnesotaUSA.
Article Synopsis
- This study focuses on the classification of glioma cases at Lagos University Teaching Hospital, utilizing the 2021 WHO brain tumor classification that combines histomorphology and molecular features, despite limited resources.
- Of the 56 brain tumor cases examined, 52 were assessed, revealing that 35% of the initial diagnoses changed after applying the WHO criteria, with some diagnoses being upgraded and others downgraded.
- The results emphasize the importance of molecular testing in improving brain tumor diagnoses in resource-limited settings like Nigeria and highlight the challenges faced in global health disparities in neuro-oncology.
Ollier Disease, Acute Myeloid Leukemia, and Brain Glioma: IDH as the Common Denominator.
Cancers (Basel)
September 2024
Department of Neurosciences, Division of Neurosurgery, Policlinico "G. Rodolico-S. Marco", University Hospital, 95123 Catania, Italy.
Article Synopsis
- - The study explores the connection between Ollier disease (OD), acute myeloid leukemia (AML), and brain glioma (BG), which are distinct types of tumors but can occur in the same patient, and aims to find shared molecular pathways for potential treatment.
- - A systematic literature review was conducted, revealing that thirty-three patients with both OD and BG were identified in previous studies, and only one documented case linked OD with AML—our case included all three diseases.
- - The IDH R132H mutation was identified as a common genetic alteration in all three types of tumors, suggesting that targeted therapies using IDH1 inhibitors could provide new treatment options, although further research with larger groups is needed to validate these findings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!